肺积1号方防治肺癌紫杉醇化疗相关心脏不良反应的临床观察

目的观察肺积1号方对肺癌紫杉醇化疗引起的心脏不良反应和心功能的干预效果。方法 64例接受紫杉醇化疗的肺癌患者随机分为对照组（n=32）和实验组（n=32）。对照组仅接受化疗,实验组在化疗同时口服肺积1号方煎剂,早晚各1次,200mL,日一剂。治疗前后分别记录心电图和超声心动图中的左心室舒张末期内径（LVDd）、左心室收缩末期内径（LVSd）、舒张早期与晚期充盈速度比值（E/A）、射血分数（LVEF）和短轴缩短率（FS）等各项指标,以及发生心脏不良反应的患者比例。结果实验组心电图异常发生率明显低于对照组（12.5%vs.31.3%,P〈0.05）,实验组化疗后LVDd、LVDs、E/A、LVEF和FS均与化疗前无统计学差异,对照组LVDd和LVDs较化疗前明显增加（P〈0.05）;实验组心脏不良反应的发生率明显低于对照组（13.6%vs.37.5%,P〈0.05）。结论肺积1号方对肺癌紫杉醇化疗所导致的心脏不良反应有一定的防治作用,并可在一定程度上减轻心脏功能下降。

Preventive effect of Feiji-1 Fang on cardiac adverse reactions related to paclitaxel in lung cancer

Objective To observe the influence of Feiji-1 Fang on cardiac adverse reactions induced by paclitaxel chemotherapy in lung cancer. Methods The patients （ n =64 ） with lung cancer treated with paclitaxel chemotherapy were randomized into control group and experimental group （ each n =32 ） . Control group was only treated with chemotherapy and experimental group was given Feiji-1 Fang （ 200 mL,bid ） besides of chemotherapy. The indexes of left ventricular end-diastolic inner diameter （ LVDd ） , left ventricular end systolic diameter （ LVSd ） , E/A ratio, left ventricular ejection fraction （ LVEF ） and fractional shortening （ FS ） of electrocardiogram （ ECG ） and echocardiogram, and proportion of patients with cardiac adverse reactions were recorded. Results The incidence of abnormal ECG was significantly lower in experimental group than that in control group （ 12.5% vs. 31.3%, P 0.05）. After chemotherapy the indexes of LVDd, LVSd, E/A ratio, LVEF and FS had not changed in experimental group, while LVDd and LVSd increased significantly in control group （ P 0.05 ） . The incidence rate of cardiac adverse reactions was lower in experimental group than that in control group （13.6% vs . 37.5%, P 0.05）. Conclusion Feiji-1 Fang has preventive effect on cardiac adverse reactions induced by paclitaxel chemotherapy, and can alleviate the dysfunction of heart.